NCT07530965Not yet recruiting
Omega-3-Fatty Acids in Children With Sickle Cell Disease
A Single Arm/ Open Label Feasibility Trial of Omega-3- Fatty Acids in Children With Sickle Cell Disease
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Sickle cell disease
- NCT number
- NCT07530965
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Dec 2026 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- current use of PPI therapy
Other illness
- individuals with known allergy to Flaxseed
Other
- current use of antibiotics except prophylactic penicillin
- current use of pre-or probiotic supplements
- pregnant or lactating females
Who the study is looking for
- \- Children 5-18 years with SCD at steady state. Steady state will be defined as not requiring an acute care visit for pain in the last 28 days.
Age in the registry: 5 years to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.